Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)

Market Cap	1.42B -8.7%
Revenue (ttm)	237.32M -45.2%
Net Income	-169.33M
EPS	-7.85
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,617
Open	67.65
Previous Close	65.58
Day's Range	64.55 - 67.65
52-Week Range	38.33 - 91.90
Beta	0.79
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About NSE:KREBSBIO

Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 202
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KREBSBIO

Financial Performance

In fiscal year 2026, NSE:KREBSBIO's revenue was 237.32 million, a decrease of -45.21% compared to the previous year's 433.12 million. Losses were -169.33 million, -37.14% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 22, 2026

Data Sources Report a data error